Elevated intracranial pressure without an identifiable mass or hydrocephalus; classically affects young, obese women with headache and papilledema.
Also known as: IIH, pseudotumor cerebri, benign intracranial hypertension, BIH
Overview
A syndrome of elevated intracranial pressure (CSF opening pressure >25 cm H2O in adults, >28 cm H2O in children) in the absence of structural, vascular, or infectious causes, with normal CSF composition and no ventriculomegaly. Diagnosed by modified Dandy criteria.
Epidemiology
Annual incidence ~1 per 100,000 overall, rising to ~20 per 100,000 in obese women of childbearing age. >90% of affected adults are women with BMI >30. Rising incidence parallels obesity prevalence.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Idiopathic Intracranial Hypertension (Pseudotumor Cerebri) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Mechanism incompletely understood. Leading hypotheses: impaired CSF outflow at arachnoid granulations, increased intracranial venous pressure from transverse sinus stenosis, and altered glymphatic drainage. Obesity and increased intra-abdominal pressure may raise central venous pressure and reduce CSF absorption.
Clinical presentation
Symptoms
Headache — daily, generalized, throbbing or pressure-like; often worse on awakening or with Valsalva
Transient visual obscurations — seconds-long graying or dimming of vision, often with postural change
Pulsatile tinnitus — whooshing in time with heartbeat
Diplopia from CN VI palsy (false localizing sign of elevated ICP)
Photopsia, blurred vision, progressive visual field loss
Malignant hypertension — Very high BP, exudates, hemorrhages, end-organ damage
Optic neuritis — Painful monocular vision loss, RAPD, central scotoma — unilateral and acute
Migraine — Episodic, no papilledema, no chronic visual loss, normal imaging
Diagnostic workup
Diagnostic criteria
Modified Dandy criteria: (1) signs/symptoms of raised ICP, (2) no localizing neurologic findings except CN VI palsy, (3) normal CSF composition, (4) CSF opening pressure elevated, (5) normal neuroimaging (no mass/hydrocephalus/vascular abnormality), (6) no other identified cause.
Labs
CBC, BMP, ESR/CRP, ANA (exclude inflammatory causes if atypical)
Thrombophilia workup if cerebral venous sinus thrombosis suspected
Imaging
MRI brain with venography (MRV) — exclude mass, hydrocephalus, and cerebral venous sinus thrombosis BEFORE lumbar puncture
Lumbar puncture in lateral decubitus position with manometry — CSF opening pressure >25 cm H2O (>28 in children); normal CSF composition
Formal visual fields (Humphrey 24-2) and dilated funduscopy with OCT of the optic nerve at diagnosis and serially
Diagnostic algorithm
flowchart TD
A[Headache + papilledema<br/>± transient visual obscurations] --> B[MRI brain + MRV<br/>(exclude mass, hydrocephalus,<br/>venous thrombosis)]
B --> C{Imaging normal?}
C -->|No| D[Treat underlying cause]
C -->|Yes| E[Lumbar puncture<br/>with manometry]
E --> F{Opening pressure<br/>>25 cm H2O,<br/>normal CSF?}
F -->|No| G[Reconsider diagnosis]
F -->|Yes| H[IIH confirmed<br/>(Modified Dandy)]
H --> I[Weight loss<br/>+ acetazolamide<br/>± topiramate]
I --> J{Progressive<br/>vision loss?}
J -->|Yes| K[Optic nerve sheath<br/>fenestration or<br/>CSF shunt or<br/>venous sinus stent]
J -->|No| L[Serial fields,<br/>OCT, fundus exam]
Diagnostic and management algorithm for idiopathic intracranial hypertension.
Treatment
First-line
Weight loss — sustained loss of 6-10% of body weight reduces papilledema and headache
Acetazolamide 250-500 mg PO BID, titrated up to 4 g/day as tolerated — first-line carbonic anhydrase inhibitor; monitor for paresthesias, metabolic acidosis, hypokalemia, kidney stones
Topiramate — alternative or adjunct; helps headache and may aid weight loss
Discontinue offending medications (tetracyclines, retinoids, exogenous vitamin A)
Headache co-management with usual abortive and preventive strategies
Sight-threatening (fulminant) IIH
Emergent ophthalmology and neurosurgery consult
Optic nerve sheath fenestration — for progressive vision loss with manageable headache
CSF shunting (VP or LP shunt) — for severe headache + vision loss; higher revision rate
Venous sinus stenting — for documented stenosis with pressure gradient (selected centers)
Serial high-volume LPs as temporizing measure if surgical delay
Pregnancy
Acetazolamide may be used after the first trimester per ACOG/NORDIC pregnancy committee guidance
Close ophthalmologic monitoring; weight management deferred
Vaginal delivery generally safe; epidural anesthesia not contraindicated
Second-line / adjunct
Bariatric surgery for refractory disease with severe obesity (BMI ≥35-40)
GLP-1 receptor agonists (semaglutide, tirzepatide) — emerging adjunct for weight loss in IIH
Complications
Permanent vision loss — the most feared complication; affects up to 25% of severely affected patients
Vision loss — not headache — is the most dangerous feature. Visual fields drive urgency of intervention.
Always perform MRV before lumbar puncture in suspected IIH to exclude cerebral venous sinus thrombosis.
Empty sella, posterior globe flattening, and bilateral transverse sinus stenosis are imaging clues to longstanding raised ICP.
Pulsatile tinnitus is a highly characteristic but underrecognized symptom.
The NORDIC trial established acetazolamide + weight loss as first-line for mild-moderate IIH.
References
NORDIC Trial — Wall M et al. Effect of acetazolamide on visual function in patients with IIH and mild visual loss. JAMA 2014;311:1641-1651.
Friedman 2013 — Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013;81:1159-1165.
AAO/AAN guidance — Joint AAO/AAN guidance on management of papilledema in IIH (consensus statements).
Practice Neurology questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.